نتایج جستجو برای: reimbursement
تعداد نتایج: 7689 فیلتر نتایج به سال:
BACKGROUND As healthcare spending continues to increase, reimbursement cuts have become 1 type of healthcare reform to contain costs. Little is known about the long-term impact of cuts in reimbursement, especially under a global budget cap with fee-for-service (FFS) reimbursement, on processes and outcomes of care. The FFS-based reimbursement cuts have been implemented since July 2002 in Taiwan...
The special series “Pharmaceutical Pricing and Reimbursement Policies” published throughout 2022, was organised by invitation of the Brazilian Journal Hospital Pharmacy Health Services, to characterise medicines pricing reimbursement in Brazil other countries discuss implementation, effects, gaps opportunities for improvement. included an editorial, a perspective on Pharmaceutical Policies (PPR...
Objectives The aim of this publication is to describe two reimbursement categories in Poland, chemotherapy drugs and drug programs, and to assess strengths and weaknesses of them from the payer’s and patients’ perspective. Policies targeted: The abstract presents evaluation of reimbursement categories which interface between outpatient and in-patient sectors, and influence of these reimbursemen...
Coverage with evidence development and parallel review for molecular diagnostics aid regulation and reimbursement.
Reimbursement models are changing. Clinical outcomes will affect your financial performance in a fee-for-value world. Yet, fee-for-service reimbursement still dominates today. Navigating the transition to this new healthcare provisioning and reimbursement model can be accomplished by first creating an effective roadmap. This roadmap includes a current state assessment and the development of a f...
Objectives This study aims to describe a specific system of reimbursement of highly innovative drugs (HID) in the Czech Republic, representing a time-limited reimbursement under special conditions. The second objective is to evaluate the total number of drugs approved as HID, as well as the number of drugs entering or failing to enter the system of regular reimbursement. The third objective is ...
BACKGROUND The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding countries. Separate calculations were also performed for three sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncol...
The change from a predominately fee-for-service payment environment to managed care has significantly reduced revenues for many clinical laboratories. Medicare is rapidly becoming the most favorable payor in areas with high managed-care penetration. This trend has not gone unnoticed by Congress, and congressional and regulatory initiatives are rapidly moving to reduce federal laboratory reimbur...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید